 Patent Application Title |
Patent App Num. |
Date |
 Synthetic gagpol genes and their uses | 20130122585 | 20130516 |
 The present invention relates to synthetic gag and gagpol genes optimized for high level expression via codon optimization and the uses thereof for the efficient generation of vector particles. The invention further relates to the generation of packaging cells and vaccines based on the synthetic gag and gagpol genes.
... |
| Method and device for optimizing a nucelotide sequence for the purpose of expression in a protein | 20130123483 | 20130516 |
 The invention relates to a method for optimizing a nucleotide sequence for expression of a protein on the basis of the amino acid sequence of the protein, in which for a particular region there is specification of a test sequence with m optimization positions on which the codon occupation is varied, a quality function being used to ascertain the optimal codon occupation on these optimization positions, and one or more codons of this optimal occupation being specified as codons of the optimized nucleotide sequence. These steps are iterated, with the codons of the optimized nucleotide sequence which are specified in the preceding steps remaining unchanged in subsequent iteration steps. The invention additionally relates to a device for carrying out this method.
... |
| Polypeptide producing cells | 20130109058 | 20130502 |
 The current invention describes a nucleic acid comprising in a 5′ to 3′ direction a) a first nucleic acid encoding a heterologous polypeptide without an in frame stop codon, b) a second nucleic acid beginning with a 5′ splice donor site and terminated by a 3′ splice acceptor site comprising an in frame translational stop codon and a polyadenylation signal, and c) a nucleic acid encoding i) at least a fragment of a transmembrane domain, or ii) a signal peptide for a GPI-anchor.
... |
| Vaccine produced using optimized immobilization antigen cdna of cryptocaryon irritans and producing method and use thereof | 20130071483 | 20130321 |
 The present invention provides an optimized immobilization antigen cDNA sequence of cryptocaryon irritans, which has been processed codon replacement and caused the cDNA to express in prokaryotic and eukaryotic cell and translate a protein has similar immunogenicity as the immobilization antigen purified from the theront of Cryptocaryon irritans. The present invention further provides a DNA vaccine produced using the cDNA to prevent fish form cryptocaryon irritans infection.
... |
| Method for optimising gene expression using synonymous codon optimisation | 20130074218 | 20130321 |
 The present invention discloses a method for modulating the quality of a selected phenotype that is displayed by an organism or part thereof and that results from the expression of a polypeptide-encoding polynucleotide by replacing at least one codon of that polynucleotide with a synonymous codon that has a higher or lower preference of usage by the organism or part thereof to produce the selected phenotype than the codon it replaces. The present invention is also directed to the use of a codon-modified polynucleotide so constructed for modulating the quality of a selected phenotype displayed by an organism or part thereof.
... |
Subscribe to updates on this page: Codon RSS  |
| Rna including nucleoside compound, method for regulating amount of protein produced from the rna, and nucleoside compound | 20130052710 | 20130228 |
| where A represents an aryl group or a heteroaryl group, # represents a site where the group represented by the formula (I) is attached to the carbon atom at the position 8 of the purine nucleus or the carbon atom at the position 5 or 6 of the pyrimidine nucleus, and two Xs, which are identical to or different from each other, each represents a nitrogen atom or CH whose H may be substituted by alkyl.
... |
| Kras primers and probes | 20130029336 | 20130131 |
| The present invention provides oligonucleotide primers or probes for the detection of a mutation of the KRAS gene. The invention also provides a method for detecting a mutation in the KRAS gene using the oligonucleotide primers or probes disclosed therein. Furthermore, the present invention encompasses a method for predicting the sensitivity of a tumor in a patient to epidermal growth factor receptor-directed chemotherapy, comprising obtaining DNA from the tumor; and determining whether there is a mutation in codon 12 and/or a mutation in codon 13 in exon 2 of the KRAS gene in the DNA using a method utilizing at least one of the oligonucleotide primers and/or probes of the present invention.
... |
| Nucleic acid construct, recombinant vector, and recombinant e. coli producing chicken anemia virus vp1 protein | 20130023036 | 20130124 |
| Disclosed herein is an expression cassette adapted to be expressed in an E. coli host cell and having a first nucleic acid fragment encoding a full-length chicken anemia virus (CAV) VP1 protein. In particular, the first nucleic acid fragment has a 5′-region that encodes a N-terminal amino acid sequence of the full-length CAV VP1 protein and is codon-optimized as compared to a corresponding 5′-region of a wild-type CAV vp1 gene, thus to encode the full-length VP1 protein. Specifically, the optimized codons are introduced into the corresponding 5′-region of the wild-type CAV vp1 gene by codon replacements.
... |
| Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection | 20130017217 | 20130117 |
| The invention relates to plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens, which are useful in the invention include, but are not limited to pp65, glycoprotein B (gB), IE1, and fragments, variants or derivatives of any of these antigens. In certain embodiments, sequences have been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further directed to methods of inducing an immune response to HCMV in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized HCMV antigen as described above. The invention is also directed to pharmaceutical... |
| Methods and composition to enhance production of fully functional p-glycoprotein in pichia pastoris | 20130011909 | 20130110 |
| The present invention provides codon optimization to increase protein production by providing a target gene, wherein the expression of the target gene is to be optimized; determining one or more low-frequency codons in the target gene; providing a codon usage frequency table; replacing each of the one or more low-frequency codons in the target gene with a corresponding high-frequency codons that code for the same amino acid; and harmonizing the a distribution of codon frequencies to those of the set of highly expressed native gene over an open reading frame in the target gene to form an optimized gene, wherein the optimized gene encodes an amino acid sequence identical to the respective wild-type (native) amino acid sequence.
... |
| Readthrough inducing agent and drug for treating genetic disease caused by nonsense mutation | 20130005953 | 20130103 |
| A readthrough inducing agent for inducing readthrough of a premature stop codon generated by nonsense mutations, the readthrough inducing agent comprising a compound having a structure expressed by the following Structural Formula (A), and a drug for treating a genetic disease caused by nonsense mutations, the drug comprising the readthrough inducing agent.
... |
| Use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with inhibitors of calcineurin or inhibitors of the mammalian target of rapamycin (mtor) complexes | 20120309683 | 20121206 |
| This invention relates to methods and compositions for the treatment, management, reduction, or prevention of injuries to one or more major organs of the body, e.g., the brain, heart, lung, kidneys, liver, and gastrointestinal tract, of a mammal (e.g., a human) caused by one or more calcineurin or mammalian target of rapamycin (mTOR) complex inhibitors. The methods include administering an effective amount of one or more pituitary adenylate cyclase-activating polypeptide (PACAP)-like compounds to the mammal. Combination therapy with one or more PACAP-like compounds, either alone or in combination with one or more other prophylactic/therapeutic agents, plus one or more inhibitors of either calcineurin or the mTOR complexes can be used to treat organ transplantation, autoimmune diseases, graft-versus-host disease, Behçet's disease, hematological cancers, noninfectious uveitis, sarcoidosis, tuberous... |
| Transgenic rodent expressing truncated disc1 | 20120304317 | 20121129 |
| The invention provides transgenic rodents, particularly mice, expressing truncated versions of the Disrupted-in-Schizophrenia-1 (DISC1) gene and showing Schizophrenia-related neural and behavioral phenotypes. The rodents of the invention have (1) a plurality of copies of a heterologous truncated Disc1 genomic DNA sequence which includes at least 1 stop codon after exon 8 such as to encode a Disc1 polypeptide truncated before exon 9; (2) 2 copies of endogenous Disc1 genomic DNA sequence encoding full length Disc1 polypeptide. Also provided are related materials and methods.
... |
Subscribe to updates on this page: Codon RSS |
| Determining codon distribution and/or base pair distance between codons in a nucleic acid | 20120295251 | 20121122 |
| The present invention relates to methods for the design and/or production of a probe or primer that is capable of hybridizing to a plurality of sites in a sample comprising nucleic acid. Furthermore, the present invention provides methods for detecting and amplifying nucleic acid using such a probe or primer, for example, for identification of a strain, species or genera. Probe or primer sequences are determined by reference to codon usage bias of a target nucleic acid. In addition, the present invention provides methods for determining codon distribution and/or base pair distance between codons in a nucleic acid.
... |
| Oligonucleotides and methods for detecting kras and pik3ca mutations | 20120288863 | 20121115 |
| Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.
... |
| Methods for treating methylmalonic acidemia | 20120289476 | 20121115 |
| Methods for treating methylmalonic acidemia in which at least one allele of a gene associated with MMA (e.g., the MUT, MMAA, or MMAB gene) contains a mutation (e.g., nonsense mutation) that results in a premature stop codon in RNA encoded by an allele of the gene associated with MMA involving the administration of a compound that promotes readthrough of RNA (e.g., messenger RNA) containing a premature stop codon encoded by an allele of the gene associated with MMA are described. The compound can be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment.
... |
| Methods and compositions for determining hypersusceptibility of hiv-1 to non-nucleoside reverse transcriptase inhibitors | 20120283250 | 20121108 |
| This invention relates to methods for determining hypersusceptibility of HIV-1 viruses to non-nucleoside reverse transcriptase inhibitors (NNRTIs) based on the viral genotypes. The methods generally comprise detecting, in a gene encoding reverse transcriptase of the HIV-1, the presence of a mutation at codon 65, 69, or 74 alone or in combination with one or more mutations at certain other codons. Combinations of mutations associated with hypersusceptibility to NNRTIs are also disclosed.
... |
| Methods and compositions for determining virus susceptibility to integrase inhibitors | 20120276522 | 20121101 |
| Methods and compositions for the efficient and accurate determination of HIV susceptibility to an integrase inhibitor and/or HIV replication capacity are provided. In certain aspects, the methods involve detecting in a biological sample a nucleic acid encoding an HIV integrase that comprises a primary mutation at codon 143, wherein the mutation at codon 143 does not encode arginine (R) or cysteine (C), and wherein the presence of the integrase-encoding nucleic acid in the biological sample indicates that the HIV has a decreased susceptibility to an integrase inhibitor or altered replication capacity relative to a reference HIV. In certain embodiments, the HIV also contains one or more secondary mutations in integrase. Also provided are methods for determining the selective advantage of a mutation or mutation profile based... |
| Attenuated influenza viruses and vaccines | 20120269849 | 20121025 |
| The present provides attenuated influenza viruses comprising a modified viral genome containing a plurality of nucleotide substitutions. The nucleotide substitutions result in the rearrangement of preexisting codons of one or more protein encoding sequences and changes in codon pair bias. Substitutions of non-synonymous and synonymous codons may also be included. The attenuated influenza viruses enable production of improved vaccines and are used to elicit protective immune responses.
... |
| Stable immunogenic protein having multiple cysteines molecules process therefor and composition thereof | 20120269856 | 20121025 |
| The invention describes a stable immunogenic protein having multiple cysteines molecules wherein the protein is having stability up to two years and purity more than 98% particularly rPvRII and/or rPfF2. It also discloses a method for producing said immunogenic protein comprising the following steps: culturing the host E. coli cells containing a desired recombinant gene construct comprising a codon optimized gene sequence of rPvRII and/or rPfF2 to produce cells in high density; inducing expression rPvRII and/or rPfF2 as inclusion bodies; harvesting the cells and isolating the said inclusion bodies; separating rPvRII and/or rPfF2 from inclusion bodies by repeated sequential washing and solubilizing with chaotrophic agents comprising guanidine hydrochloride and/or urea; purifying the protein by subjecting to metal-chelate affinity chromatography; re-folding of the purified rPvRII and/or rPfF2... |
| Recombinant butyrylcholinesterases and truncates thereof | 20120252094 | 20121004 |
| Isolated nucleic acids encoding polypeptides that exhibit butyrylcholinesterase (BChE) enzyme activity are disclosed, along with molecular criteria for preparing such nucleic acids, including codon optimization. Methods of preparing modified and/or truncated BChE molecules having selected properties, especially selective formation of monomers, are also described. Vectors and cells containing and/or expressing the nucleic acids are also disclosed.
... |
| Optimized messenger rna | 20120252117 | 20121004 |
| The present invention is directed to a synthetic nucleic acid sequence which encodes a protein wherein at least one non-common codon or less-common codon is replaced by a common codon. The synthetic nucleic acid sequence can include a continuous stretch of at least 90 codons all of which are common codons.
... |
| Hepatitis c virus codon optimized non-structural ns3/4a fusion gene | 20120208870 | 20120816 |
| Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.
... |
| Systems and methods for measuring translation of target proteins in cells | 20120183957 | 20120719 |
| The present invention relates to systems and methods for measuring the rate of translation of a target protein in cells, which are based on the detection of translation of one or more predetermined codon pairs during synthesis of the target protein. The detection is provided by a FRET signal emitted from labeled tRNA molecules which are juxtaposed during synthesis of the protein.
... |
| Xylitol producing microorganism introduced with arabinose metabolic pathway and production method of xylitol using the same | 20120171739 | 20120705 |
| The present invention relates to an efficient production method of xylitol by using the xylitol producing microorganism introduced with arabinose metabolic pathway to inhibit the production of arabitol, the byproduct, and instead to use arabinose only for cell metabolism in xylose/arabinose mixed medium. More precisely, to express efficiently L-arabinose isomerase (araA), L-ribulokinase (araB) and L-ribulose-5-phosphate 4-epimerase (araD) in Candida tropicalis, codon optimization was performed. Then, each gene was inserted in the gene expression cassette containing the glyceraldehyde-3-phosphate dehydrogenase promoter and the selection marker URA3, which was introduced into Candida sp. microorganism. As a result, arabitol, the byproduct interrupting the purification and crystallization of xylitol could be inhibited, making the production method of xylitol of the present invention more efficient. The xylitol producing microorganism introduced with arabinose... |
| Exon skipping therapy for functional amelioration of semifunctional dystrophin in becker and duchenne muscular dystrophy | 20120172415 | 20120705 |
| Methods for stabilizing unstable proteins or for restoring functionality to non-functional or poorly functioning (semi-functional) proteins using exon skipping technology are provided. The methods involve the administration of antisense oligonucleotides to cause exon skipping, thereby removing one or more exons responsible for protein instability or lack of functionality. For example, exons encoding protease recognition sites may be removed. The method is useful for treating diseases caused by protein instability, such as Becker Muscular Dystrophy, or for treating Duchenne Muscular Distrophy patients with semi-functional dystrophin due to treatment with other exon skipping or stop codon readthrough therapies.
... |
| Materials and methods for treating diseases caused by genetic disorders using aminoglycosides and derivatives thereof which exhibit low nephrotoxicity | 20120157398 | 20120621 |
| Various aspects related to the preparation of congeners of the aminoglycosides gentamicin such as the congener C2 and using this compound or derivatives thereof and pharmaceutically active salts to treat diseases that involve genetic mutations which introduce a missense or premature stop codon into a gene. Still other aspects include treating human or animal patients with the gentamicin congener C2 and derivatives and pharmaceutical salt thereof to overcome, or to at least mitigate, the symptoms of disease and disorders such as some forms of Becker's or Duchenne muscular dystrophy, Hurler's Syndrome and Cystic Fibrosis that have as their etiology the presence of a premature stop codon in a gene whose proper expression is necessary for good health.
... |
| Foamyvirus vectors and methods of use | 20120141440 | 20120607 |
| The disclosure of the present application provides foamyvirus vectors, as well as methods and kits involving the same. In at least one embodiment, a plurality of recombinant vectors comprises an expression sequence encoding at least one component of a foamyvirus particle, wherein at least one codon of the expression sequence is optimized for expression in homo sapiens.
... |
| Live bacterial vaccines for viral infection prophylaxis or treatment | 20120142080 | 20120607 |
| A live bacterium, having a DNA construct stabilized against transduction of other bacteria, having a promoter sequence and encoding a fusion peptide, comprising a bacterial secretion peptide portion and a non-bacterial immunogenic polypeptide portion, having a nucleotide sequence coding for the non-bacterial immunogenic polypeptide portion which has at least one codon optimized for bacterial expression. The bacterium has a secretion mechanism which interacts with at least the bacterial secretion peptide portion to cause a secretion of the fusion peptide from the bacterium, and a genetic virulence attenuating mutation. The bacterium is adapted to act as an animal vaccine, to transiently infect a tissue of the animal, and cause an immunity response to the non-bacterial immunogenic polypeptide portion in the animal to a non-bacterial organism associated with... |
| Methods for producing secreted polypeptides | 20120122191 | 20120517 |
| The present invention relates to methods for producing a polypeptide, comprising: (a) cultivating a fungal host cell in a medium conducive for the production of the polypeptide, wherein the fungal host cell comprises a nucleic acid construct comprising a first nucleotide sequence encoding a signal peptide operably linked to a second nucleotide sequence encoding the polypeptide, wherein the first nucleotide sequence is foreign to the second nucleotide sequence and the 3′ end of the first nucleotide sequence is immediately upstream of the initiator codon of the second nucleotide sequence. The present invention also relates to the isolated signal peptide sequences and to constructs, vectors, and fungal host cells comprising the signal peptide sequences operably linked to nucleotide sequences encoding polypeptides.
... |
| Methods of incorporating amino acid analogs into proteins | 20110008828 | 20110113 |
| The invention provides a method of incorporating nonstandard amino acids into a protein by utilizing a modified aminoacyl-tRNA synthetase to charge the nonstandard amino acid to a modified tRNA, which forms strict Watson-Crick base-pairing with a codon that normally forms wobble base-pairing with natural tRNAs.
... |
| Sustained release solid formulations and methods of manufacturing the same | 20110008424 | 20110113 |
| Disclosed are a sustained release solid formulation comprising a drug, for example, oxycodone or its pharmaceutically acceptable salt, in a water-insoluble matrix, which comprises a wax type excipient and copovidone, and thus, has increased compressibility and fluidity and reduced adhesiveness, and a method of preparing the same.
... |
| Down-regulation and silencing of allergen genes in transgenic peanut seeds | 20110004959 | 20110106 |
| An allergen-free transgenic peanut seed is produced by recombinant methods. Peanut plants are transformed with multiple copies of each of the allergen genes, or fragments thereof, to suppress gene expression and allergen protein production. Alternatively, peanut plants are transformed with peanut allergen antisense genes introduced into the peanut genome as antisense fragments, sense fragments, or combinations of both antisense and sense fragments. Peanut transgenes are under the control of the 35S promoter, or the promoter of the Ara h2 gene to produce antisense RNAs, sense RNAs, and double-stranded RNAs for suppressing allergen protein production in peanut plants. A full length genomic clone for allergen Ara h2 is isolated and sequenced. The ORF is 622 nucleotides long. The predicted encoded protein is 207 amino acids long and... |
| Novel compounds derived from indole and pharmaceutical compositions containing them | 20110003843 | 20110106 |
| wherein X represents N, CR8 or N+R8, wherein R8 represents a hydrogen atom, a hydroxyl or alkyl or methoxy group optionally substituted with a phenyl group; R2, R3 and R4 independently represent a hydrogen atom or a halogen atom or an optionally substituted alkyl, amine, alkene, ester, sulfonamide, ether or benzyl group; R5 represents a hydrogen atom or an optionally substituted, saturated or unsaturated alkyl group, amine, benzyl group; R6 represents an optionally substituted C1-C3 alkyl group; R7 represents a hydrogen atom or an optionally substituted C1-C3 alkyl group and R7 is absent when the ring A is in the b position, and A represents a ring; R9 and R10 represent together a carbon bond or independently represent an R11 OR11, SR11 group; wherein R11 represents... |
| Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, method of making and use thereof | 20110002991 | 20110106 |
| The presently described technology provides phenylethanoic acid, phenylpropanoic acid, phenylpropenoic acid, a salt thereof, a derivative thereof or a combination thereof chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs or compositions of hydrocodone which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
... |
| Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof | 20110002990 | 20110106 |
| The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
... |
| Human tissue factor-producing knock-in non-human animal | 20100333220 | 20101230 |
| A non-human animal that produces human tissue factor (TF) without substantially producing non-human animal tissue factor, said animal having a genome in which cDNA encoding human TF has been inserted upstream of the translation initiation codon for the non-human animal genomic TF gene.
... |
| Pharmaceutical composition | 20100330205 | 20101230 |
| A pharmaceutical composition comprising 1.5 parts by weight powdered fennel, 2.0 parts by weight powdered rhubarb, 1.0 part by weight powdered glycyrrhiza, 2.0 parts by weight powdered phellodendron bark, 1.0 part by weight powdered zedoary, 1.5 parts by weight powdered picrasma wood, 1.0 part by weight powdered matricaria chamomilla, 1.5 parts by weight powdered geranium herb, 1.0 part by weight powdered ginseng, 1.5 parts by weight powdered citrus unshiu peel, 1.0 part by weight powdered scutellaria root, 1.0 part by weight powdered magnolia bark, 2.0 parts by weight powdered oyster shell, 1.0 part by weight powdered cyperus rhizome, 2.0 parts by weight powdered platycodon root, 2.0 parts by weight powdered melia azedarach, 1.0 part by weight powdered cnidium rhizome, 2.0 parts by weight sodium bicarbonate and... |
| Small rna-dependent translational regulatory system in cell or artificial cell model | 20100323356 | 20101223 |
| An object of the present invention is to construct an mRNA which specifically responds to a short RNA sequence and can activate, repress, and regulate the translation of the desired gene, and to construct an artificial cell model system using a liposome comprising the mRNA and a cell-free translational system encapsulated therein. The present invention provides: an mRNA comprising a target RNA-binding site located immediately 5′ to the ribosome-binding site, and a nucleotide sequence located 5′ to the target RNA-binding site, the nucleotide sequence being complementary to the ribosome-binding site; an mRNA comprising a small RNA-binding site located 3′ to the start codon, and a nucleotide sequence located 3′ to the small RNA-binding site, the nucleotide sequence encoding a protein; and a liposome comprising any of... |
| Puumala virus full-length m segment-based dna vaccines | 20100323024 | 20101223 |
| The invention contemplates a new synthetic, codon-optimized Puumala virus (PUUV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The PUUV ORF was cloned into a plasmid to form the first stable PUUV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a molecular vaccine system, and is useful to protect mammals against infection with Puumala virus.
... |
| Long life high capacity electrode, device, and method of manufacture | 20100312168 | 20101209 |
| Electrodes, particularly electrochemically active electrodes, may benefit from one or more pretreatment cycles in which the electrode is substantially oxidized, reduced or otherwise exhausted prior to use in an end use application, for example active agent delivery via iontophoresis. For instance, electrode lifetime may be advantageously increased, even when used to delivery relatively high currents or used at high current densities. Such may be necessary to delivery therapeutically effect dosage regimes, for instance of oxycodone. Use of a nonwoven fibrous substrate printed with a sacrificial ink may be advantageous relative to other substrates. Use of certain Ag/AgCl inks may be advantageous over other Ag/AgCl inks.
... |
| Vaccines against chlamydia infection | 20100310593 | 20101209 |
| The present invention is directed to providing a vaccine to enhance the immune response of an animal in need of protection against a Chlamydia infection. The present invention is also directed toward an isolated nucleic acid encoding a polypeptide comprising at least 70% identity to any one of SEQ ID NOS: 2, 11, 13, 19, or 21, wherein the polypeptide is soluble in the absence of denaturing agents. In some aspects of the invention, the polynucleotide is codon-optimized. In some embodiments, the present invention is related to the polypeptide encoded by the polynucleotide of the invention. Administration of polypeptides of the present invention can be used as a method to treat or prevent a Chlamydia infection in an animal in need thereof.
... |
| System and method for producing synthetic microorganisms capable of translating proteins containing non-standard amino acids | 20100297698 | 20101125 |
| The disclosed invention relates to the generation of host cells containing rare codons and/or absent tRNAs, and the use of orthogonal tRNA systems that can insert a non-standard amino acid into a growing peptide chain. This invention combined with the capacity to synthesize whole genomes has important implications in synthetic biology, as it allows the rewriting of the genetic code of existing or newly designed organisms.
... |
| Methods for increasing protein titers | 20100297697 | 20101125 |
| The invention relates to methods of increasing the titre of a protein of interest in a cell as well as the improved production and purification of optimised biomolecules, one component of which is the domain CH3. A frequently observed effect in biomolecules is the cleaving of the C-terminal amino acid(s), e.g. the C-terminal lysine. The usually incomplete processing of the heavy chain of antibodies for example leads to product heterogeneity. To prevent this product heterogeneity the corresponding codon of the C-terminal lysine of the heavy antibody chain has been deleted by recombinant DNA technology. These optimised antibodies lead to a product titre which is higher than in the wild-type. In addition, they prove advantageous during purification by having better elution characteristics as a result of the... |
| Compositions of orthogonal lysyl-trna and aminoacyl-trna synthetase pairs and uses thereof | 20100291559 | 20101118 |
| Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal lysyl-tRNAs, orthogonal lysyl-aminoacyl-tRNA synthetases, and orthogonal pairs of lysyl-tRNAs/synthetases, which incorporate homoglutamines into proteins are provided in response to a four base codon. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins with homoglutamines using these orthogonal pairs.
... |
| Compositions and methods for the identification of inhibitors of retroviral infection | 20100291032 | 20101118 |
| Methods of identifying inhibitors of retroviral propagation, tRNA used in the methods, and kits, including the tRNA, which can be used in the methods, are disclosed. Methods of treating or preventing retroviral infections by administering an effective amount of the inhibitors, and pharmaceutical compositions including the inhibitors, are also disclosed. The methods involve forming a mixture comprising a linear sequence of a tRNA anticodon stem loop fragment that is not capable of forming a stem-loop, a target nucleic acid molecule capable of binding to the tRNA anticodon stem loop fragment, and a test compound. The mixture is incubated under conditions that allow binding of the tRNA anticodon stem loop fragment and the target nucleic acid molecule in the absence of the test compound. Assays can then... |
| Protein expression system | 20100287670 | 20101111 |
| The inventions is based on an expression enhancer sequence derived from the RNA-2 genome segment of a bipartite RNA virus, in which a target initiation site in the RNA-2 genome segment has been mutated. Deletion of appropriate start codons upstream of the main RNA2 translation initiation can greatly increase in foreign protein accumulation without the need for viral replication. Also provided are methods, vectors and systems, including the ‘hyper-translatable’ Cowpea Mosaic Virus (‘CPMV-HT’) based protein expression system.
... |
| Codon-optimized dna molecules encoding the receptor binding domains of clostridium difficile toxins a and b, and methods of use thereof | 20100278868 | 20101104 |
| In one aspect, the invention provides a DNA molecule. The DNA molecule includes a nucleotide sequence that encodes the receptor-binding domain of Clostridium difficile toxin A or toxin B in which at least about 10% of the in-frame codons for each amino acid residue has a higher percentage use in the human genome than the corresponding in-frame codons of C. difficile toxin A or toxin B having a known sequence. Methods for generating antibodies to Clostridium difficile toxin A or toxin B, methods for reducing the risk of a C. difficile infection, and methods for treating a C. difficile are also provided.
... |
| Method | 20100273996 | 20101028 |
| A method of producing a replication defective retrovirus comprising transfecting a producer cell with the following: iii) a retroviral genome; iv) a nucleotide sequence coding for retroviral gag and pot proteins; and iii) nucleotide sequences encoding other essential viral packaging components not encoded by the nucleotide sequence of (ii); characterised in that the nucleotide sequence coding for retroviral gag and pot proteins is codon optimised for expression in the producer cell.
... |
| Codon-optimized nucleic acid for coding apo-clytin-ii and method for using the same | 20100273202 | 20101028 |
| A codon-optimization of nucleic acid for coding apo-clytin-II protein is provided. Luminescent activity of clytin-II is remarkably enhanced. Accordingly, compared with the conventional use of the wild-type clytin-II, an intracellular calcium ion can be detected much more easily.
... |
| Optimized expression of hpv 58 l1 in yeast | 20100272749 | 20101028 |
| Synthetic DNA molecules encoding the HPV58 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV58 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV58 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV58 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity and are also useful for treatment of existing HPV infections.
... |
| Isoindoline compounds for the treatment of spinal muscular atrophy and other uses | 20100267712 | 20101021 |
| Disclosed is a compound of Formula (I) in which W and R1-R6 are defined herein. Also disclosed is a method of treating spinal muscular atrophy, as well as methods of using such compounds to increase SMN expression, increase EAAT2 expression, or increase the expression of a nucleic acid that encodes a translational stop codon introduced directly or indirectly by mutation or frameshift.
... |
| Ruthenium catalysts for the production of hydrocodone, hydromorphone or a derivative thereof | 20100261905 | 20101014 |
| The present disclosure generally relates to catalytic methods for producing opioid derivatives. More particularly, the present disclosure relates to the preparation of hydrocodone, hydromorphone, or a derivative thereof, by means of an isomerization of codeine, morphine, or a derivative thereof, respectively, using a ruthenium catalyst.
... |
| Expression of genes from gram negative bacteria in fungi | 20100261259 | 20101014 |
| The present invention provides a method for the recombinant expression of polypeptides originating from gram negative bacteria, in a fungal host suitable for industrial production. In a first aspect the present invention relates to a method for recombinant expression of a polypeptide from a gram negative bacterium in a fungal host cell, comprising the steps: i) providing a nucleic acid sequence encoding the polypeptide, said nucleic acid sequence comprising a first nucleic acid sequence encoding a fungal signal peptide and a second nucleic acid sequence encoding the polypeptide, having at least one modified codon, wherein the modification does not change the amino acid encoded by said codon and the nucleic acid sequence of said codon is different compared to the corresponding codon in the wild type... |
| Baculoviral vectors comprising repeated coding sequences with differential codon biases | 20100261254 | 20101014 |
| The present invention relates to production of proteins in insect cells whereby repeated coding sequences are used in baculoviral vectors. In particular the invention relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral rep proteins that increase the productivity of parvoviral vectors.
... |
| Host-vector system for cloning and expressing genes | 20100255561 | 20101007 |
| A system for ligase-free cloning and/or expressing a target gene is described herein. A preferred version of the invention includes an E. coli host. The host preferably includes a T7 RNA polymerase gene comprising a T7gpl coding sequence, a lacUV5 promoter, and a lac operator. The host preferably further includes a lacI gene comprising a lacI coding sequence with an ATG start codon, a promoter derived from the lacql allele, and a translational enhancer derived from a 5′ RNA leader sequence of T7 gene 10. The invention further includes a low-copy plasmid vector comprising a T7 promoter a lac operator operationally linked to the T7 promoter. The system is configured to inhibit target gene expression when uninduced and to permit gene expression upon induction by auto-induction.
... |
| Codon modified immunogenic compositions and methods of use | 20100247621 | 20100930 |
| The present invention features immunogenic compositions comprising codon modified genes that encode viral proteins and/or glycoproteins or fragments. The immunogenic compositions of the invention are useful in various methods of treatment, such as preventing or treating viral infection. Also provided in the present invention are kits and instructions for use.
... |
| Antisense antibacterial method and compound | 20100234280 | 20100916 |
| An antibacterial antisense conjugate and method of using the same for treating a bacterial infection in a mammalian host are disclosed. The conjugate includes an antisense oligonucleotide conjugated to a carrier peptide that significantly enhances the antibacterial activity of the oligonucleotide. The antisense oligonucleotide contains 10-20 nucleotide bases and has a targeting nucleic acid sequence complementary to a target sequence containing or within 10 bases, in a downstream direction, of the translational start codon of a bacterial mRNA that encodes a bacterial protein essential for bacterial replication, where the compound binds to a target mRNA with a Tm of between 50° to 60° C. The carrier peptide is an arginine-rich peptide containing between 6 and 12 amino acids.
... |
| Stable, fertile, high polyhydroxyalkanoate producing plants and methods of producing them | 20100229258 | 20100909 |
| Transgenic plants that produce high levels of polyhydroxybutyrate and methods of producing them are provided. In a preferred embodiment the transgenic plants are produced using plastid transformation technologies and utilize genes which are codon optimized. Stably transformed plants able to produce greater than 10% dwt PHS in tissues are also provided.
... |
| Method for producing polyunsaturated fatty acids | 20100227924 | 20100909 |
| The invention relates to a method for producing eicosapentanoic acid, docosapentanoic acid and/or docohexanoic acid in transgenic plants. According to said method, the plant is provided with at least one nucleic acid sequence coding for a polypeptide with a Δ6 desaturase activity, at least one nucleic acid sequence coding for a polypeptide with a Δ6 elongase activity, at least one nucleic acid sequence coding for a polypeptide with a Δ5 desaturase activity, and at least one nucleic acid sequence coding for a polypeptide with a Δ5 elongase activity, the nucleic acid sequence coding for a polypeptide with a Δ5 elongase activity being modified in relation to the nucleic acid sequence in the organism from which the sequence originates, such that it is adapted to the codon... |
| Method of increasing gene expression using modified codon usage | 20090325244 | 20091231 |
| The present invention relates to a method of increasing the amount of at least one polypeptide in the host cell by expressing a modified nucleotide sequence encoding for a polypeptide in a host cell with said modified nucleotide sequence being derived from a different non-modified nucleotide sequence encoding for a polypeptide of identical amino acid sequence such that the codon usage of the modified nucleotide sequence is adjusted to the codon usage of abundant proteins in the host cell.
... |
| Design, synthesis and assembly of synthetic nucleic acids | 20090317873 | 20091224 |
| Methods of synthesizing oligonucleotides with high coupling efficiency (>99.5%) are provided. Methods for purification of synthetic oligonucleotides are also provided. Instrumentation configurations for oligonucleotide synthesis are also provided. Methods of designing and synthesizing polynucleotides are also provided. Polynucleotide design is optimized for subsequent assembly from shorter oligonucleotides. Modifications of phosphoramidite chemistry to improve the subsequent assembly of polynucleotides are provided. The design process also incorporates codon biases into polynucleotides that favor expression in defined hosts. Design and assembly methods are also provided for the efficient synthesis of sets of polynucleotide variants. Software to automate the design and assembly process is also provided.
... |
| Abuse resistant melt extruded formulation having reduced alcohol interaction | 20090317355 | 20091224 |
| The present invention relates to compositions for oral administration. The invention preferably comprises at least one abuse-resistant drug delivery composition for delivering a drug having potential for dose dumping in alcohol, related methods of preparing these dosage forms, and methods of treating a patient in need thereof comprising administering the inventive compositions to the patient. Most preferably, the dosage form includes verapamil. These formulations have reduced potential for abuse. In another formulation, preferably the abuse relevant drug is an opioid and the non-abuse relevant drug is acetaminophen or ibuprofen. More preferably, the opioid is hydrocodone, and the non-abuse relevant analgesic is acetaminophen. In certain preferred embodiments, the dosage forms are characterized by resistance to solvent extraction; tampering, crushing or grinding. Certain embodiments of the inventions provide... |
| Gpr22 and methods relating thereto | 20090313708 | 20091217 |
| Methods for generating an expression-enhanced GPR22 nucleic acid, as well as substituted GPR22 nucleic acids providing for enhanced expression of the encoded GPR22 polypeptide, are provided. In practicing the subject methods, a nucleic acid encoding a mammalian GPR22 receptor polypeptide (e.g., a wild-type nucleic acid) is expression-enhanced by identifying the various codons of the coding region for the GPR22 amino acid sequence and substituting nucleotides so as to enhance expression without changing the amino acid sequence of the encoded GPR22 polypeptide. Methods, compositions, and kits using the same for screening of modulators of GPR22 are also provided.
... |
| Compounds for the treatment of spinal muscular atrophy and other uses | 20090312323 | 20091217 |
| Compounds of Formula (I) or (II) useful for the treatment of spinal muscular atrophy or other uses, as well as methods of using such compounds to increase SMN expression, increase EAAT2 expression, or increase the expression of a nucleic acid that encodes a translational stop codon introduced by mutation or frameshift.
... |
| Polypeptide producing cells | 20090311725 | 20091217 |
| The current invention describes a nucleic acid comprising in a 5′ to 3′ direction a) a first nucleic acid encoding a heterologous polypeptide without an in frame stop codon, b) a second nucleic acid beginning with a 5′ splice donor site and terminated by a 3′ splice acceptor site comprising an in frame translational stop codon and a polyadenylation signal, and c) a nucleic acid encoding i) at least a fragment of a transmembrane domain, or ii) a signal peptide for a GPI-anchor.
... |
| Genetic markers for high oleic acid content in plants | 20090307806 | 20091210 |
| The present invention relates to a mutated nucleic acid sequence of a delta-12 oleate desaturase enzyme (FAD2)—encoding nucleic acid from a Cruciferae plant, wherein said mutated nucleic acid sequence comprises the non-conservative mutation of at least one nucleotide of at least one codon representing an amino acid selected from the group consisting of: —the amino acid at position 259 of the amino acid sequence of said FAD2, —the amino acid at position 216 of the amino acid sequence of said FAD2, —the amino acid at position 90 of the amino acid sequence of said FAD2, —the amino acid at position 116 of the amino acid sequence of said FAD2, —the amino acid at position 276 of the amino acid sequence of said FAD2.
... |
| Granule and orally disintegrating tablet comprising oxycodone | 20090304792 | 20091210 |
| The present invention relates to granules comprising oxycodone, as well as to orally disintegrating tablets including same and optionally acetaminophen.
... |
| Chimeric transfer rna and use thereof for the production of rna by a cell | 20090298920 | 20091203 |
| The present invention relates to the use of a nucleic acid encoding a chimeric transfer RNA (tRNA), which chimeric tRNA originates from the modification of a tRNA by insertion of an RNA into the stem-loop of the anticodon of the tRNA and/or by substitution of all or part of the stem-loop of the anticodon of the tRNA with an RNA, for the production of the RNA or of a part of the RNA, in a cell.
... |
| Dual opioid pain therapy | 20090291975 | 20091126 |
| Provided are pharmaceutical compositions and methods for the alleviation of pain in a patient with optimal ratios of morphine and oxycodone that provide superior analgesic efficacy and lower incidence of adverse side effects compared to morphine and oxycodone alone. The pharmaceutical compositions comprise morphine and oxycodone, or pharmaceutically acceptable salts thereof, in ratios of about 3 to 2 to about 1 to 2, morphine to oxycodone by weight.
... |
| Influenza nucleic acids, polypeptides, and uses thereof | 20090291472 | 20091126 |
| Codon-optimized nucleic acids encoding influenza polypeptides and uses of the nucleic acids and polypeptides for inducing immune responses are provided herein.
... |
| Method for achieving improved polypeptide expression | 20090286280 | 20091119 |
| The present invention relates to methods of optimization of a protein coding sequences for expression in a given host cell. The methods apply genetic algorithms to optimise single codon fitness and/or codon pair fitness sequences coding for a predetermined amino acid sequence. In the algorithm generation of new sequence variants and subsequent selection of fitter variants is reiterated until the variant coding sequences reach a minimum value for single codon fitness and/or codon pair fitness. The invention also relates to a computer comprising a processor and memory, the processor being arranged to read from and write into the memory, the memory comprising data and instructions arranged to provide the processor with the capacity to perform the genetic algorithms for optimisation of single codon fitness and/or codon... |
| Novel nucleic acid base pair | 20090286247 | 20091119 |
| A novel artificial nucleic acid base pair which is obtained by forming a selective base pair by introducing a group having steric hindrance (preferably a group having steric hindrance and static repulsion and a stacking effect) and can be recognized by a polymerase such as DNA polymerase; a novel artificial gene; and a method of designing nucleic acid bases so as to form a selective base pair with the use of steric hindrance, static repulsion and stacking effect at the base moiety of the nucleic acid. An artificial nucleic acid comprising these bases; a process for producing the same; a codon containing the same; a nucleic acid molecule containing the same; a process for producing a non-natural gene by using the same; a process for producing... |
| method for the production of a monoclonal antibody to cd20 for the treatment of b-cell lymphoma | 20090285795 | 20091119 |
| The present invention relates to the recombinant method used for the production of soluble form of an antibody that binds to CD20 for treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma (NHL). The treatment will comprise the use of immunologically active anti-CD20 antibodies; or radiolabeled anti-CD20 antibodies and or cooperative strategies where both labeled and non-labeled antibodies will be used for treatment of NHL. The procedure describes the de novo synthesis of the nucleic acid sequence encoding anti-CD20, transformation of the constructed nucleic acid sequences into competent bacteria and the sub-cloning of the same into mammalian expression vectors for expression of the desired protein. DNA constructs comprising the control elements associated with the gene of interest has been disclosed. The... |
| Recombinant production of serum albumin | 20090280534 | 20091112 |
| The present invention relates to modified nucleotide sequences encoding serum albumin, wherein the mRNA sequence has been codon optimized for expression in a filamentous host cell. Furthermore the present invention relates to serum albumin produced in filamentous fungi or loaded by contacting serum albumin with an extract of a filamentous fungi culture. In an-other aspect the present invention relates to the use of said serum albumin in serum free cell culture media and also to a method of drying and agglomerating serum albumin thereby im-proving wettability and dispersability.
... |
| Recombinant production of serum albumin | 20090280534 | 20091112 |
| The present invention relates to modified nucleotide sequences encoding serum albumin, wherein the mRNA sequence has been codon optimized for expression in a filamentous host cell. Furthermore the present invention relates to serum albumin produced in filamentous fungi or loaded by contacting serum albumin with an extract of a filamentous fungi culture. In an-other aspect the present invention relates to the use of said serum albumin in serum free cell culture media and also to a method of drying and agglomerating serum albumin thereby im-proving wettability and dispersability.
... |
| Synthetic gene | 20090274726 | 20091105 |
| The present invention relates to synthetic genes, processes for designing said synthetic genes and their uses in gene therapy and improved DNA vaccination. The novel synthetic genes and processes are codon shuffled so that they have reduced homology relative to a naturally occurring gene encoding the same protein without altering the overall codon usage frequency of the gene. In particular the present invention relates to improved polynucleotides and methods for the treatment or prevention of disease comprising codon-shuffled GM-CSF nucleic acid sequences. Nucleic acid vaccines of the present invention may comprise a combination of a nucleotide sequence encoding codon-shuffled GM-CSF, a nucleotide encoding an antigen against which it is desired to raise an immune response and a toll-like receptor (TLR) agonist.
... |
| Synthetic gene | 20090274726 | 20091105 |
| The present invention relates to synthetic genes, processes for designing said synthetic genes and their uses in gene therapy and improved DNA vaccination. The novel synthetic genes and processes are codon shuffled so that they have reduced homology relative to a naturally occurring gene encoding the same protein without altering the overall codon usage frequency of the gene. In particular the present invention relates to improved polynucleotides and methods for the treatment or prevention of disease comprising codon-shuffled GM-CSF nucleic acid sequences. Nucleic acid vaccines of the present invention may comprise a combination of a nucleotide sequence encoding codon-shuffled GM-CSF, a nucleotide encoding an antigen against which it is desired to raise an immune response and a toll-like receptor (TLR) agonist.
... |
| Process for the selection of hiv-1 subtype c isolates, selected hiv-1 subtype isolates, their genes and modifications and derivatives thereof | 20090270488 | 20091029 |
| Embodiments of the invention provide processes for the selection of HIV-1 subtype (clade) C isolates, selected HIV-1 subtype C isolates, their genes and modifications and derivatives thereof for use in prophylactic and therapeutic vaccines to produce proteins and polypeptides for the purpose of eliciting protection against HIV infection or disease. A process for the selection of HIV subtype isolates comprises the steps of isolating viruses from recently infected subjects; generating a consensus sequence for at least part of at least one HIV gene by identifying the most common codon or amino acid among the isolated viruses; and selecting the isolated virus or viruses with a high sequence identity to the consensus sequence. HIV-1 subtype C isolates, designated Du422, Du 151 and Du 179 (assigned Accession Numbers... |
| Process for the selection of hiv-1 subtype c isolates, selected hiv-1 subtype isolates, their genes and modifications and derivatives thereof | 20090270488 | 20091029 |
| Embodiments of the invention provide processes for the selection of HIV-1 subtype (clade) C isolates, selected HIV-1 subtype C isolates, their genes and modifications and derivatives thereof for use in prophylactic and therapeutic vaccines to produce proteins and polypeptides for the purpose of eliciting protection against HIV infection or disease. A process for the selection of HIV subtype isolates comprises the steps of isolating viruses from recently infected subjects; generating a consensus sequence for at least part of at least one HIV gene by identifying the most common codon or amino acid among the isolated viruses; and selecting the isolated virus or viruses with a high sequence identity to the consensus sequence. HIV-1 subtype C isolates, designated Du422, Du 151 and Du 179 (assigned Accession Numbers... |
| Oligonucleotide library encoding randomised peptides | 20090264313 | 20091022 |
| The invention relates to a method of producing an oligonucleotide library comprising a plurality of oligonucleotides, each oligonucleotide in the library having at least one predetermined position, a randomisation codon selected from a defined group of codons, the codons within said defined group coding for different amino acids. Vector, host cells containing such libraries and kits for the production of such libraries are also provided.
... |
| Combined hydrocodone and analgesic formulation and method | 20090264454 | 20091022 |
| The present invention is directed to co-administration of hydrocodone and a second analgesic agent for the treatment of pain. A pharmaceutical composition suitable for the co-administration contains a therapeutically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of at least one second analgesic agent. A ratio of the hydrocodone or pharmaceutically acceptable salt thereof to the at least one second analgesic agent in the composition is within a range that provides greater pain relief than that obtainable by the administration of the hydrocodone or second analgesic agent alone. Examples of pharmaceutical compositions for co-administration of the agents are those containing hydrocodone and indomethacin (“Indocodone”), hydrocodone and naproxen (“Naprocodone”), hydrocodone and diclofenac (“Diclodone”) and hydrocodone and tramadol (“Tramacodone”).
... |
| Method for producing recombinant rnase a | 20090259035 | 20091015 |
| The invention relates to a method for producing recombinant RNase A in E. coli. Said method is characterised in that it uses a DNA sequence, which codes for an RNase A of bovine origin and which is adapted to the codon usage in E. coli. The invention relates to nucleic acid molecules, which contain a nucleic acid sequence that has been adapted to the codon usage in E. coli and to recombinant nucleic acid molecules, which contain an nucleic acid molecule of this type and permit the expression of the recombinant RNase A in E. coli.
... |
| Enhancement of microbial ethanol production | 20090226992 | 20090910 |
| A thermophilic microorganism lacks lactate dehydrogenase activity and preferably contains an active pyruvate formate lyase pathway. The thermophilic microorganism contains a gene encoding an NAD-linked formate dehydrogenase. The gene encoding an NAD-linked formate dehydrogenase is preferably a codon optimised version of the gene encoding a thermostable NAD-linked formate dehydrogenase. DNA constructs allow stable expression of the gene encoding an NAD-linked formate dehydrogenase in the thermophilic microorganism. The DNA constructs are based upon use of an insertion sequence to achieve stable expression or recombination to insert the gene encoding an NAD-linked formate dehydrogenase into the lactate dehydrogenase gene, thus achieving gene knockout and new functionality in a single step. The microorganisms are useful in fermentation of sugars to produce ethanol.
... |
| Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone | 20090227615 | 20090910 |
| In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
... |
| Method for treating cancers with increased ras signaling | 20090220503 | 20090903 |
| Disclosed herein are methods for treating a subject with, or at risk for, developing a tumor which has aberrantly increased Ras signaling. The method involves obtaining a biological sample from the subject, determining whether the biological sample contains cells which have aberrantly increased Ras signaling, and administering an agent that selectively inhibits Protein Kinase C (PKC) delta to the subject upon determination of the aberrantly increased Ras signaling, to thereby inhibit PKC-delta in the cell. The increased Ras signaling may result from expression of activated Ras, e.g. resulting from mutations in codon 12, 13, 59, 61, 63, 116, 117, or 146. Such mutations can be determined by detection of a nucleotide sequence encoding an activated form of Ras protein, or by detection of the activated Ras... |
| Recombinant method for the production of a monoclonal antibody to cd52 for the treatment of chronic lymphocytic leukemia | 20090220520 | 20090903 |
| The present invention relates to the recombinant method used for the production of soluble form monoclonal antibody that binds to CD52. The procedure describes the de novo synthesis of the nucleic acid sequence encoding anti-CD 52, transformation of the constructed nucleic acid sequences into competent bacteria and the sub-cloning of the same into mammalian expression vectors for expression of the desired protein. DNA constructs comprising the control elements associated with the gene of interest has been disclosed. The nucleic acid sequence of interest has been codon optimized to permit expression in the suitable mammalian host cells.
... |
| Herbal formulations and methods for supplementing caffeinated beverages | 20090220667 | 20090903 |
| Herbal formulations for use in caffeinated beverages are disclosed. A formulation for improving cognitive functions can include Ganoderma lucidum, Semen Zizyphi Spinosae, Herba Cistanches, Gastrodia Elata and Rhizoma Polygonati. A formulation for promoting digestive functions can include Radix Astragali, Rhizoma Dioscoreae, Radix Codonopsis, Fructus Setariae Germinatus, Radix Gentianae and Glycyrrhiza uralensis. A formulation for mitigating undesired effects of the caffeinated beverage can include Radix Rehmannia Preparata, Rhizoma Dioscoreae, Fructus Corni, Rhizoma Polygonati, Radix Polygoni Multiflori, Pericarpium Citri Reticulatae, Pericarpium Citri Reticulatae, Radix Codonopsis, Glycyrrhiza uralensis and Cordyceps sinensis. A formulation for promoting healthy reactions to stress can include Semen Zizyphi Spinosae, Ramulus Uncariae cum Uncis, Radix Paeoniae Alba, Bulbus Lilii, Albizzia julibrissin, Ganoderma lucidum, Glycyrrhiza uralensis and Spica prunellae. A formulation for improving immune system functions... |
| Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms | 20090221621 | 20090903 |
| Disclosed are methods of sustained release administration of opioids, including but not limited to hydromorphone and oxycodone, that exhibit improved properties with respect to co-ingestion with aqueous alcohol.
... |
| Antiviral agents and vaccines against influenza | 20090208531 | 20090820 |
| These vaccines target H5N1, H1, H3 and other subtypes of influenza and are designed to elicit neutralizing antibodies, as well as cellular immunity. The DNA vaccines express hemagglutinin (HA) or nucleoprotein (NP) proteins from influenza which are codon optimized and/or contain modifications to protease cleavage sites of HA which affect the normal function of the protein. Adenoviral constructs expressing the same inserts have been engineered for prime boost strategies. Protein-based vaccines based on protein production from insect or mammalian cells using foldon trimerization stabilization domains with or without cleavage sites to assist in purification of such proteins have been developed. Another embodiment of this invention is the work with HA pseudotyped lentiviral vectors which would be used to screen for neutralizing antibodies in patients and to... |
| Methods for altering gene expression and methods of treatment utilizing same | 20080318884 | 20081225 |
| The present disclosure describes methods for altering the expression of a target gene comprising a rare cluster of codons, including, but not limited to, trinucleotide repeats. The method utilizes, in part, on amino acid deprivation or the limiting of specific charged tRNAs. The methods for altering target gene expression may be used in treatment methods to treat diseases in a subject organism in need of such treatment. Such methods for altering target gene expression have not been heretofore recognized in the art. Exemplary diseases that may be treated using the methods of the present disclosure include any disease where altering the expression of the target gene would provide treatment. Such diseases include all forms of cancer, ageing, infectious disease, metabolic disorders, inflammation, neurological disorders, diabetes, psychiatric... |
| Preparation of oxycodone | 20080312443 | 20081218 |
| b) exposing the mixture to hydrogenation reagents for a period of at least 1 hour.
... |
| Ibuprofen-hydrocodone-antihistamine composition | 20080305159 | 20081211 |
| A pharmaceutical composition for use in relieving cold and cough symptoms in a mammal includes ibuprofen, hydrocodone bitartrate and an antihistamine (or a decongestant). The ibuprofen is in a therapeutically effective amount sufficient to act as an analgesic and an anti-inflammatory. The hydrocodone bitartrate is in a therapeutically effective amount sufficient to act as an antitussive and an analgesic. The antihistamine is in a therapeutically effective amount to act as an antihistamine. A fatty excipient may be added to the active ingredients to facilitate encapsulation. Multiple layers of the fatty excipient may be employed in varying release formulations and to facilitate identification of the composition.
... |
| Method for obtaining structural information concerning an encoded molecule and method for selecting compounds | 20080305957 | 20081211 |
| In one aspect, the present invention relates to a method for obtaining structural information about an encoded molecule. The encoded molecule may be produced by a reaction of a plurality of chemical entities and may be capable of being connected to an identifier oligonucleotide containing codons informative of the identity of the chemical entities which have participated in the formation of the encoded molecule. In a certain embodiment, primers are designed complementary to the codons appearing on the identifier oligonucleotide, and the presence, absence or relative abundance of a codon is evaluated by mixing a primer with the identifier oligonucleotide in the presence of a polymerase and substrate (deoxy)ribonucleotide triphosphates and measuring the extension reaction. In another aspect, the invention provides a method for selecting compounds... |
| Preparation of oxycodone | 20080306265 | 20081211 |
| wherein the step of maintaining is performed in the absence of hydrogenation reagents.
... |
| Influenza vaccines | 20080299151 | 20081204 |
| Described herein are vaccines and the use of naked DNA and/or RNA encoding hemagglutinin (HA) from pandemic influenza, e.g., the 1918 H1N1 and/or the 1957 H2N2 and/or the 1968 H3N2 influenza A virus, as a vaccine component against present day and coming H1, H2, H3, H5, N1, N2 containing influenza A infections in humans and swine optionally with the naked DNA and/or RNA encoding Neuraminidase (NA) and/or matrix protein (M) and/or the nucleoprotein (NP) from pandemic influenza virus included. If the vaccine components are used as DNA or RNA vaccines with or without the corresponding protein, the codons can optionally be “humanized” using preferred codons from highly expressed mammalian genes and the administration of this DNA vaccine can be by saline or buffered saline injection of... |
| Health tea and method for preparing the same | 20080299284 | 20081204 |
| Disclosed are health teas and a method for preparation thereof. The health tea comprises 4 to 6 wt. % of ginkgo leaves; 2 to 4 wt. % of Codonopsis lanceolata; 1 to 2 wt. % of Ganoderma lucidum; 3 to 5 wt. % of Solomon's seal; 1 to 3 wt. % of roots of sprout beans; 4 to 6 wt. % of cucumber; 1 to 2 wt. % of onion; 2 to 4 wt. % of Hedysarum; 1 to 3 wt. % of Maximowiczia typica; 4 to 6 wt. % of pear fruits; 2 to 4 wt. % of red beans; 6 to 8 wt. % of persimmon leaves; 6 to 8 wt. % of persimmon fruits; 1 to 3 wt. % of sugar; and the... |
| Design, synthesis and assembly of synthetic nucleic acids | 20080300842 | 20081204 |
| Methods of synthesizing oligonucleotides with high coupling efficiency (>99.5%) are provided. Methods for purification of synthetic oligonucleotides are also provided. Instrumentation configurations for oligonucleotide synthesis are also provided. Methods of designing and synthesizing polynucleotides are also provided. Polynucleotide design is optimized for subsequent assembly from shorter oligonucleotides. Modifications of phosphoramidite chemistry to improve the subsequent assembly of polynucleotides are provided. The design process also incorporates codon biases into polynucleotides that favor expression in defined hosts. Design and assembly methods are also provided for the efficient synthesis of sets of polynucleotide variants. Software to automate the design and assembly process is also provided.
... |
| Transgenic mouse models of hepatitis c virus (hcv) and identification of hvc therapeutics | 20080295185 | 20081127 |
| Disclosed herein is the discovery of novel NS3/4A compositions with enhanced expression abilities. Embodiments of the invention include codon optimized NS3/4A compositions and compositions with the Semliki forest virus replicon. Additional embodiments include transgenic organisms containing these NS3/4A compositions, methods or using these transgenic mice to screen and refine drugs, and the drugs refined by these methods. Additional embodiments include protease activity dependent molecules that can indicate the presence or absence of a protease inhibitor.
... |
| Modular genomes for synthetic biology and metabolic engineering | 20080286871 | 20081120 |
| The invention provides methods and compositions for assembling a modular replacement genome in a host microorganism. After such assembly, the host organism's genome is inactivated or ablated to permit full control of host cellular functions by the replacement genome. A modular replacement genome comprises an assembly of nucleic acid fragments, or segments, derived from one or more natural organisms or from synthetic polynucleotides or from a combination of both. Such an assembly, or set, of segments making up a replacement genome comprises a substantially complete set of genes and regulatory elements for carrying out minimal life functions under predefined culture conditions. The invention provides modular genomes having modules that are amenable to facile replacement, deletion, and/or additions. Such modules may be synthetic polynucleotides and may be... |
| Human sweet and umami taste receptor variants | 20080287310 | 20081120 |
| Identified herein are different forms of sweet and umami receptor encoding sequences that occur in different human populations. In particular, there are provided several single nucleotide polymorphisms (SNPs) that occur within the exons/coding sequence (and are therefore coding SNPs, cSNPs) of one of the three T1R genes. Some SNPs cause amino acid substitutions, while others introduce a chain termination codon, rendering a truncated product. Differences in these genes are believed to affect the sense of taste of individuals, such that individuals with different SNPs (or different haplotypes) are believed to perceive the taste of sweet or umami (e.g., glutamate) substances differently than the rest of the population. The ability to assay this allelic information is useful in the development of flavorings and flavor enhancers, as it... |
| Drug for ameliorating male climacteric disorders | 20080274213 | 20081106 |
| It is intended to provide a highly safe pharmaceutical drug or food that inhibits reduction in blood testosterone level and prevents or ameliorates symptoms and so on associated with male climacteric disorders. The present invention provides a drug for inhibiting reduction in blood testosterone level and a drug for ameliorating male climacteric disorders comprising a plant belonging to the genus Codonopsis or an extract thereof.
... |
| Methods for producing secreted polypeptides | 20080268526 | 20081030 |
| The present invention relates to methods for producing a polypeptide, comprising: (a) cultivating a fungal host cell in a medium conducive for the production of the polypeptide, wherein the fungal host cell comprises a nucleic acid construct comprising a first nucleotide sequence encoding a signal peptide operably linked to a second nucleotide sequence encoding the polypeptide, wherein the first nucleotide sequence is foreign to the second nucleotide sequence and the 3′ end of the first nucleotide sequence is immediately upstream of the initiator codon of the second nucleotide sequence. The present invention also relates to the isolated signal peptide sequences and to constructs, vectors, and fungal host cells comprising the signal peptide sequences operably linked to nucleotide sequences encoding polypeptides.
... |
| Method | 20080269473 | 20081030 |
| A method of producing a replication defective retrovirus comprising transfecting a producer cell with the following: iii) a retroviral genome; iv) a nucleotide sequence coding for retroviral gag and pol proteins; and iii) nucleotide sequences encoding other essential viral packaging components not encoded by the nucleotide sequence of (ii); characterised in that the nucleotide sequence coding for retroviral gag and pol proteins is codon optimised for expression in the producer cell.
... |
| Multiparticulates | 20080260815 | 20081023 |
| Extrusion of a mix containing a pharmaceutically active agent can be achieved using a plasticising excipient in an amount sufficient to act as plasticiser and also act as lubricant, thereby avoiding the need for inclusion of a lubricant. The invention provides multiparticulates with controlled release properties, substantially free of lubricant. The present invention is preferably directed to extruded multiparticulates containing an opioid such as oxycodone, an ammonium methacrylate copolymer such as Eudragit® RSPO, a plasticising excipient such as preferably stearyl alcohol and a water permeability modifier such as preferably Eudragit® RLPO. The obtained multiparticulates show a release rate profile which is pH-independent.
... |
| 2-micron family plasmid and use thereof | 20080261861 | 20081023 |
| The present invention provides a 2 μm-family plasmid comprising a polynucleotide sequence insertion, deletion and/or substitution between the first base after the last functional codon of at least one of either a REP2 gene or an FLP gene and the last base before the FRT site in an inverted repeat adjacent to said gene.
... |
| Production of recombinant collagenases colg and colh in escherichia coli | 20080233614 | 20080925 |
| The present invention provides codon-optimized genes designed to help maximize heterologous protein expression level. The present invention provides codon-optimized recombinant colG and colH collagenase sequences.
... |
| Optimized expression of hpv 58 l1 in yeast | 20080226660 | 20080918 |
| Synthetic DNA molecules encoding the HPV 52 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV 52 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. In alternative embodiments of the invention, the nucleotide sequence of the synthetic molecule is altered to eliminate transcription termination signals that are recognized by yeast. The synthetic molecules may be used to produce HPV 52 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV 52 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity and may also be useful for treatment of existing HPV infections.
... |
| Recombinant viral-based malaria vaccines | 20080220014 | 20080911 |
| The present invention relates to novel vaccines against malaria infections, based on recombinant viral vectors, such as alpha viruses, adenoviruses or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium infections, such as infections by P. falciparum or P. yoelii. Novel codon-optimized circumsporozoite genes are disclosed. Preferably, replication-defective adenoviruses are used, derived from serotypes that encounter low titers of neutralizing antibodies. The invention, therefore, also relates to the use of different adenoviral serotypes that are administered to elicit a strong immune response, either in single vaccination set-ups or in prime-boost set-ups in which compositions based on different serotypes can be applied.
... |
| Hepatitis c virus codon optimized non-structural ns3/4a fusion gene | 20080213290 | 20080904 |
| Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.
... |
| Composition of radix codonopsis and radix astragali, a method for preparation thereof and its application | 20080206374 | 20080828 |
| The invention relates to a composition of Radix Codonopsis and Radix Astragali of which the main component is prepared according to a certain weight ratio of Radix Codonopsis and Radix Astragali. The invention also provides a method of preparing the pharmaceutical composition and its applications in the preparation of an immunoregulator and mediciments for the treatment of ischemic heart diseases and acute lung injury.
... |
| Composition of radix codonopsis and radix astragali, a method for preparation thereof and its application | 20080206375 | 20080828 |
| The invention relates to a composition of Radix Codonopsis and Radix Astragali of which the main component is prepared according to a certain weight ratio of Radix Codonopsis and Radix Astragali. The invention also provides a method of preparing the pharmaceutical composition and its applications in the preparation of an immunoregulator and medicaments for the treatment of ischemic heart diseases and acute lung injury.
... |
| Enhanced production of functional proteins from defective genes | 20080207538 | 20080828 |
| This invention provides methods for enhancing production in a subject of a functional protein from a gene disrupted by a mutation, for example by the presence of a premature stop codon or by an exon skipping mutation, comprising administering to the subject an amount of an agent effective to suppress the mutation and an amount of an agent effective to increase transcription of the gene.
... |
| Optimized nucleotide sequences encoding sgp 130 | 20080199906 | 20080821 |
| Described are codon optimized sgp130 encoding nucleic acid molecules as well as a method for the highly efficient recombinant production of sgp130 in mammalian cells or bacteria using a nucleic acid molecule of the invention.
... |
| Use of oxycodone for treating visceral pain | 20080200493 | 20080821 |
| It is possible to effectively treat moderate to severe visceral pain by administering analgesic medications comprising the opioid oxycodone or pharmaceutically acceptable salts thereof. Visceral pain and especially acute (i.e. non-chronic) visceral pain can be effectively treated by administering oxycodone at a dosage which is lower than the corresponding dosage of other opioids like morphine.
... |
| Codon optimized synthetic plasmids | 20080194511 | 20080814 |
| One aspect of the current invention is an optimized synthetic mammalian expression plasmid (e.g. pAV0201). This new plasmid comprise a therapeutic element, and a replication element. The therapeutic element of the new plasmid comprises a eukaryotic promoter; a 5′ untranslated region (“UTR”); a codon-optimized-eukaryotic therapeutic gene sequence; and a poly adenylation signal. The therapeutic elements of this plasmid are operatively linked and located in a first operatively-linked arrangement. Additionally, the optimized synthetic mammalian expression plasmid comprises replication elements, wherein the replication elements are operatively linked and located in a second operatively-linked arrangement. The replication elements comprise a selectable marker gene promoter, a ribosomal binding site, and an origin of replication. The first-operatively-linked arrangement and the second-operatively-linked arrangement comprise a circular structure of the codon optimized synthetic... |
| Microbially expresses xylanases and their use as feed additives and other uses | 20080187627 | 20080807 |
| The present invention relates to codon-optimized xylanase coding sequences and the expression of xylanases in microbes and yeast. The invention further relates to using multiple copies of the xylanase expression construct for high levels of protein expression. The invention also relates to the use of xylanases as feed or food additives. The invention also relates to methods of expression of enzymes to increase thermotolerance by expressing them in organisms that glycosylate proteins compared to expression that the same enzyme without the glycosylation. Further, the invention relates to methods of preparing feed, enzyme feed additives, and methods of reducing the feed conversion ration or increasing weight gain of animals.
... |
| Method for catalytic preparation of hydromorphone and hydrocodone | 20080188661 | 20080807 |
| that selectively convert morphine/codeine to hydromorphone/hydrocodone, and methods of use thereof.
... |
| Optimized expression of hpv 31 l1 in yeast | 20080166371 | 20080710 |
| Synthetic DNA molecules encoding the HPV31 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV31 L1 protein, wherein said polynucleotides are free from internal transcription termination signals that are recognized by yeast. Also provided are synthetic polynucleotides encoding HPV31 L1 wherein the polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV31 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV31 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity.
... |
| Brassica juncea lines with high oleic acid profile in seed oil | 20080168587 | 20080710 |
| In various aspects, the invention provides Brassica juncea plants, seeds, cells, nucleic acid sequences and oils. Edible oil derived from plants of the invention may have significantly higher oleic acid content than other B. juncea plants. In one embodiment, the B. juncea line MJ02-357-3 contains a mutant allele MJ02-313-1/BjFAD2-a at the BjFAD2-a gene locus, having a single base-pair change (a G to A substitution in the ORF at position 281 in reference to the first ATG start codon) relative to the wild type sequence. The change is predicted to encode a Glycine-94 Aspartic acid mutation in the sequence of the predicted BjFAD2-a protein. In another embodiment, the B. juncea line MJ02-357-3 contains a mutant allele MJ02-357-3/BjFAD2-a at the BjFAD2-a gene locus, having a single base-pair change... |
| Analyzing traslational kinetics using graphical displays of translational kinetics values of codon pairs | 20070298503 | 20071227 |
| Graphical displays are provided of translational kinetics values of codon pairs in a host organism plotted as a function of polypeptide-encoding nucleotide sequence. Such translational kinetics values of codon pair frequencies correspond to the predicted translational pausing properties of a codon pair in a host organism. The graphical displays provided reflect the relative over-representation or under-representation of each codon pair in an organism, thereby facilitating analysis of translational kinetics of an mRNA into polypeptide by comparing graphical displays of different codon pairs in sequences encoding the polypeptide. The graphical displays of translational kinetics values also can display codon pair properties on comparable numerical scales, thereby facilitating analysis of translational kinetics of an mRNA into polypeptide in different organisms by comparing comparably scaled graphical displays of the... |
| Codon optimization method | 20070292918 | 20071220 |
| A heterologous expression in a host Pseudomonas bacteria of an optimized polynucleotide sequence encoding a protein.
... |
| Synthetic gagpol genes and their uses | 20070293448 | 20071220 |
| The present invention relates to synthetic gag and gagpol genes optimized for high level expression via codon optimization and the uses thereof for the efficient generation of vector particles. The invention further relates to the generation of packaging cells and vaccines based on the synthetic gag and gagpol genes.
... |
| Method for separation and purification of hydrocodone by preparative chromatography | 20070293676 | 20071220 |
| A process for the purification of an impure preparation containing hydrocodone by means of a reverse phase preparative chromatography process is provided. In an illustrative embodiment a chromatographic column is loaded with a stationary phase, typically a silica particle having an organic ligand bound thereto. The impure preparation is acidified and passed through the column with a loading ratio of from about 10 to about 1000. The column is eluted, typically with an aqueous solution of acetonitrile, and the purified hydrocodone is obtained in a specified fraction.
... |
| Sustained release oxycodone composition with acrylic polymer and surfactant | 20070281016 | 20071206 |
| The invention is a controlled release composition comprising a therapeutic amount of an active ingredient in a controlled release matrix. The matrix comprises a combination of a pharmaceutically acceptable acrylic polymer and a metal hydroxide. The amount of surfactant, relative to a given amount of acrylic polymer, is selected for and corresponds to a predetermined release rate for said active ingredient. The compound is preferably used to provide controlled release dosage of oxycodone through a matrix of ammonio methacrylic polymer and sodium lauryl sulfate.
... |
| Sustained release oxycodone composition with acrylic polymer and metal hydroxide | 20070281017 | 20071206 |
| The invention is a controlled release composition comprising a therapeutic amount of an active ingredient in a controlled release matrix. The matrix comprises a combination of a pharmaceutically acceptable acrylic polymer and a metal hydroxide. The amount of metal hydroxide, relative to a given amount of acrylic polymer, is selected for and corresponds to a pre-determined release rate for said active ingredient. The compound is preferably used to provide controlled release dosage of oxycodone through a matrix of ammonio methacrylic polymer and magnesium hydroxide.
... |
| Sustained release formulations of opioid and nonopioid analgesics | 20070281018 | 20071206 |
| The present invention relates to SRSR solid dosage forms for administering pharmaceutical agents, particularly Hydrocodone and acetaminophen, methods for preparing said dosage forms, and methods for providing therapeutic agents to patients in need of treatment.
... |
| Preparation of oxycodone | 20070281958 | 20071206 |
| A process for preparing oxycodone or an oxycodone salt, wherein the oxycodone or oxycodone salt has low levels of impurities (especially 14-hydroxycodeinone) is disclosed. The process comprises the steps of: a) preparing a mixture comprising oxycodone and a solvent and adjusting the pH of the mixture to less than 6; and subsequently b) exposing the mixture to hydrogenation reagents for a period of at least 1 hour. This process provides oxycodone with very low levels of α,β-unsaturated ketone impurities. Oxycodone or an oxycodone salt produced according to the process of the invention has low levels of α,β-unsaturated ketones and is advantageously incorporated into pharmaceutical products.
... |
| Compositions and methods for modifying the content of polyunsaturated fatty acids in biological cells | 20070274952 | 20071129 |
| The present invention features compositions (e.g., nucleic acids encoding fat-1, optionally and operably linked to a constitutively active or tissue-specific promoter or other regulatory sequence and pharmaceutically acceptable formulations including that nucleic acid or biologically active variants thereof) and methods that can be used to effectively modify the content of PUFAs in animal cells (i.e., cells other than those of C. elegans, for example, avian or fish cells such as myocytes, neurons (whether of the peripheral or central nervous system), adipocytes, endothelial cells, and cancer cells). The compositions and methods include a fat-1 gene that has been modified to include at least one optimized codon. The modified cells, whether in vivo or ex vivo (e.g., in tissue culture), transgenic animals containing them (fish and birds in... |
| Controlled release oxycodone compositions | 20070275062 | 20071129 |
| A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control... |
| Controlled release oxycodone compositions | 20070275065 | 20071129 |
| A method for substantially reducing the range in daily dosages required to control pain in approximately. 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean,of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour): administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain... |
| Methods for calculating codon pair-based translational kinetics values, and methods for generating polypeptide-encoding nucleotide sequences from such values | 20070275399 | 20071129 |
| Provided are methods for calculating codon pair translational kinetics values, creating a synthetic gene for expression in a host organism, and providing codon pair translational kinetic values. The methods typically are directed to refinement of statistical observed versus expected codon pair frequencies using one of several factors such as amino acid sequence homology, secondary or tertiary structural considerations, and empirical measurements. In some synthetic genes codon pairs are predicted not to cause a translational pause in the host organism, thereby providing a polynucleotide sequence encoding the desired polypeptide with desired translational kinetics properties. The methods can be performed using multiple parameter nucleotide sequence optimization methods, such as branch-and-bound methods for nucleotide sequence refinement.
... |
| Sars nucleic acids, proteins, vaccines, and uses thereof | 20070270361 | 20071122 |
| Codon-optimized nucleic acids, proteins, vaccines, and antibodies are provided herein.
... |
| Antisense restenosis composition and method | 20070265215 | 20071115 |
| The present invention provides an improved method for reducing the risk or severity of restenosis following cardiac angioplasty. The method includes administering to a target vessel region, a morpholino antisense compound having a phosphorus-containing backbone linkages, and spanning the start codon of a human c-myc mRNA. Also disclosed are novel antisense compounds and compositions, and a method for assaying the effectiveness of antisense delivery and uptake to a target vessel region.
... |
| Optimized interferon-beta gene | 20070259405 | 20071108 |
| A new nucleic acid molecule that is codon-optimized to express beta interferon in Escherichia coli with greater efficacy.
... |
| Transcription factors | 20070254336 | 20071101 |
| The present invention relates to an isolated nucleic acid sequence coding for a PntR transcription factor comprising a nucleotide sequence that is the same as, or is complementary to, or contains any suitable codon substitutions for any of those of SEQ ID NOs: 1, 3 or 5 or comprises a sequence which has at least 60% sequence homology with any of SEQ ID NOs: 1, 3 or 5, as well as corresponding polypeptides, vector systems and host cells comprising the same. In particular, the invention relates to sequences which are obtained from an Aspergillus, Trichoderma or Penicillium cell. The invention further relates to methods for disrupting PntR expression in a cell as well as methods for expression or production of a POI in a host cell... |
| Methods for identification of alport syndrome | 20070243538 | 20071018 |
| Animals with mutations in COL4α4 present with autosomal recessive Alport Syndrome (ARAS). Through sequencing of COL4α4, the mutation causative for ARAS in the English Cocker Spaniel (ECS) has been identified. The resulting protein is severely truncated due to a premature stop codon in exon 3. This nonsense mutation occurs in the 7S domain and also causes the loss of the entire collagenous and NC1 domains of the protein. Methods for the identification of animals that harbor a mutation in the COL4α4 gene are described. Mutations in the COL4α4 gene can be identified from any biological sample such as a cell or tissue that contains genomic DNA. Methods for identifying single nucleotide polymorphisms (SNPs) that are inherited with the disease are also described. A microsatellite marker that... |
| Using a reverse genetic engineering platform to produce protein vaccines and protein vaccine of avian influenza virus | 20070243587 | 20071018 |
| The present invention relates to a preparation method of protein vaccines, and comprises the steps of: (a) providing at least one amino acid sequence of an epitope of a target antigen protein; (b) converting the amino acid sequence into a nucleic acid sequence and modifying the codons; (c) synthesising a plurality of primers of the modified nucleic acid sequence; (d) synthesising the modified nucleic acid sequence in vitro; (e) inserting the synthesized fragment of the modified nucleic acid sequence into a plasmid; (f) transforming the plasmid into a host cell to produce the modified nucleic acid encoded epitope peptide; and (g) collecting and purifying the produced peptide.
... |
| Marker for selecting transformant with the use of lethal gene | 20070243604 | 20071018 |
| A DNA fragment prepared by inserting a translation termination codon into 5′ upstream side of the active site of a lethal gene, a transformant selection marker which uses the same, and a vector into which the marker is inserted. Since this lethal gene is used as a gene marker, complete extinction of transformants having no exogenous gene can be achieved, and a transformant selection marker capable of effecting stable amplification of a vector containing an exogenous gene in a host can be obtained. In addition, a vector which can effect accurate and efficient gene analyses by DNA microarray and the like is obtained.
... |
| Modular genomes for synthetic biology and metabolic engineering | 20070243617 | 20071018 |
| The invention provides methods and compositions for assembling a modular replacement genome in a host microorganism. After such assembly, the host organism's genome is inactivated or ablated to permit full control of host cellular functions by the replacement genome. A modular replacement genome comprises an assembly of nucleic acid fragments, or segments, derived from one or more natural organisms or from synthetic polynucleotides or from a combination of both. Such an assembly, or set, of segments making up a replacement genome comprises a substantially complete set of genes and regulatory elements for carrying out minimal life functions under predefined culture conditions. The invention provides modular genomes having modules that are amenable to facile replacement, deletion, and/or additions. Such modules may be synthetic polynucleotides and may be... |
| Composition having bone resorption inhibition-related effect and method for inhibiting bone resorption | 20070231414 | 20071004 |
| The present invention has for its object to provide a method which comprises using edible and safe food components as active ingredients and promotes the OPG production promoting effect, RANKL expression inhibiting effect and osteoclast differentiation inhibiting effect, which take part in the prevention of bone resorption, and a composition like that. The present invention provides a method for promoting the bone resorption inhibitory effect such as the OPG production promoting effect, RANKL expression inhibiting effect and osteoclast differentiation inhibiting effect by using a composition containing extracts from plants belonging to the genus Platycodon, plants belonging to the genus Origanum, plants belonging to the genus Thymus, plants belonging to the genus Zanthoxylum, plants belonging to the genus Arctium, plants belonging to the genus Camellia, plants belonging... |
| Regulated stop codon readthrough | 20070224635 | 20070927 |
| Methods for screening or selecting cells expressing a polypeptide of interest, e.g. for selecting cells expressing a desired level of a polypeptidé of interest, for evaluating recombinant polypeptide expression in a population of cells, or for selecting cells expressing a polypeptide with a desired binding affinity to a ligand, as well as for producing a polypeptide of interest from a selected cell, where the cells comprise an expression cassette comprising a first polynucleotide encoding the polypeptide of interest, at least one stop codon downstream of the first polynucleotide, and a second polynucleotide encoding a cell membrane anchoring peptide, a reporter peptide or an epitope tag downstream of the stop codon, and where the cells are cultured in the presence of a termination suppression agent, in particular... |
| Site-specific incorporation of fluorinated amino acids into proteins | 20070218483 | 20070920 |
| This invention relates, in part, to newly identified polynucleotides, polypeptides, variants and derivatives thereof; processes for making the polynucleotides and the polypeptides, and their variants and derivatives; and uses of the polynucleotides, polypeptides, variants and derivatives. The invention also relates to compositions of orthogonal aminoacyl-tRNA synthetases, and pairs of orthogonal aminoacyl-tRNA synthetases, and orthogonal tRNAs that incorporate fluorinated amino acids into proteins in response to selector codons. The present invention also includes translation biochemistry methods for site-specific incorporation of fluorinated amino acids, for example, 18F- or 19F-labelled amino acids, into proteins or peptides. Such amino acids may be used as an NMR probe for characterizing protein structure, dynamics, and reactivity or for radionuclide imaging (e.g., PET). Fluorinated amino acids may also be used to stabilize proteins... |
| Gene encoding phosphoenolpyruvate synthase in plant protection | 20070219359 | 20070920 |
| The present invention discloses a pathogenic gene derived from Xanthomonas campestris, a gene encoding phosphoenolpyruvate synthase. The gene encoding phosphoenolpyruvate synthase of this invention has one of the following nucleotide sequence: 1. a nucleotide sequence of SEQ ID NO:1; 2. a DNA sequence which has more than 80% homology with the nucleotide sequence of SEQ ID NO:1, and encodes a protein which has same function as phosphoenolpyruvate synthase encoded by SEQ ID NO:1. The Open Reading Frame of the DNA of SEQ ID NO:1 is from nucleotide 201 to 2576 in its 5′ end. It consists of 2379 nucleotides, the initiation codon TTG of this gene is from nucleotides 201 to 203 in its 5′ end, and the termination codon TGA of this gene is from... |
| Preparation of oxycodone | 20070219373 | 20070920 |
| A process for preparing oxycodone or an oxycodone salt, wherein the oxycodone or oxycodone salt has low levels of impurities (especially 14-hydroxycodeinone) is disclosed. The process comprises the steps of: a) preparing a mixture comprising oxycodone and a solvent and adjusting the pH of the mixture to less than 6; and subsequently b) exposing the mixture to hydrogenation reagents for a period of at least 1 hour.
... |
| Human sodium channel isoforms | 20070212723 | 20070913 |
| The present invention relates to novel isoforms in or near the 5′ untranslated region (upstream of the start codon) and the 3′ untranslated region (down stream of the start codon) which correlates with an increased risk of heart disease. These isoforms are various spliced variants of the wild-type sodium channel mRNA. Preferably, the isoforms that correlate with heart disease are E1B1 (SEQ ID NO. 1), E1B2 (SEQ ID NO. 2), E1B3 (SEQ ID NO. 3), E1B4 (SEQ ID NO. 4), E2B1 (SEQ ID NO. 5), E2B2 (SEQ ID NO. 6), E28B (SEQ ID NO. 7), E28C (SEQ ID NO. 8), and E28D (SEQ ID NO. 9).
... |
| Compounds and compositions for prevention of overdose of oxycodone | 20070203055 | 20070830 |
| The invention relates to pharmaceutical compounds and compositions comprised of a chemical moiety attached to an opioid such as oxycodone in a manner that substantially decreases the potential of the opioid to cause overdose. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent. Further the compounds and compositions of the invention are useful in preventing addiction and susceptibility to addiction.
... |
| Modified hpv e6 and e7 genes and proteins useful for vaccination | 20070196339 | 20070823 |
| Described are DNA sequences encoding an E6 or E7 fusion protein of HPV, wherein said DNA sequences are characterized by a combination of the following features: original codons are exchanged by codons which lead to an enhanced translation in a mammalian cell, they contain a deletion resulting in the production of a truncated non-functional protein, and they encode a fusion partner which is a highly immunogenic polypeptide capable of enhancing the immunogenicity of the E6 or E7 protein in the mammalian host. Furthermore, the modified E6 or E7 protein encoded by said DNA sequences as well as expression vectors containing said DNA sequences are described as well as several uses of the these compounds.
... |
| Method of detecting azt resistance in hiv | 20070196902 | 20070823 |
| Described herein is a method of determining the presence of a nucleoside reverse transcriptase inhibitor-resistant Human Immunodeficiency Virus-1 (HIV-1) virus particle in a biological sample, comprising identifying the presence in the sample of a point mutation at codon Q509 of an HIV-1 reverse transcriptase, for example and without limitation Q509L. That point mutation increases resistance to AZT about 3- to 10-fold by itself and about 50-fold in combination with the connection domain mutation A371V.
... |
| Oxycodone polymorphs | 20070197572 | 20070823 |
| Oxycodone.HCl polymorph forms are disclosed which are useful as analgesic agents either in combination with or as replacements for oxycodone.
... |
| Method for optimising gene expressing using synonymous codon optimisation | 20060292566 | 20061228 |
| The present invention discloses a method for modulating the quality of a selected phenotype that is displayed by an organism or part thereof and that results from the expression of a polypeptide-encoding polynucleotide by replacing at least one codon of that polynucleotide with a synonymous codon that has a higher or lower preference of usage by the organism or part thereof to produce the selected phenotype than the codon it replaces. The present invention is also directed to the use of a codon-modified polynucleotide so constructed for modulating the quality of a selected phenotype displayed by an organism or part thereof.
... |
| Synthetic gene encoding rhesus monkey carcinoembryonic antigen and uses thereof | 20060286114 | 20061221 |
| Synthetic polynucleotides encoding rhesus monkey carcinoembryonic antigen (CEA) are provided, the synthetic polynucleotides being condon-optimized for expression in a human cellular environment. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant CEA expression is associated with a carcinoma or its development. This invention specifically provides adenovial vector and plasmid constructs carrying codon-optimed rhesus monkey CEA and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.
... |
| Fault tolerant and combinatorial software environment system, method and medium | 20060288345 | 20061221 |
| A fault tolerant software environment, in which various program components (e.g., portions of computer programs, applications, etc) are objectized into entities represented by “codons.” This allows for improper syntax to occur, enabling, for example, combinatorial operations such as genetic programming. The present invention also contemplates such features as the ability to probabilistically execute individual codons, to switch between treating information as executable code or as data (or passing over it), provides that the individual codons can be tagged so that additional information can be associated with them, and provides for tagging of the stack.
... |
| Modified starch, uses, methods for production thereof | 20060282917 | 20061214 |
| The present invention relates to modified starch, as well as production and uses thereof. The starch has modified properties of viscosity and a modified phosphate content. The present invention also relates to a nucleic acid molecule encoding a codon-optimized form of a maize R1 protein set forth in SEQ ID NO:1.
... |
| Antisense restenosis composition and method | 20060269587 | 20061130 |
| The present invention provides an improved method for reducing the risk or severity of restenosis following cardiac angioplasty. The method includes administering to a target vessel region, a morpholino antisense compound having uncharged phosphorus-containing backbone linkages, and spanning the start codon of a human c-myc mRNA. Also disclosed are novel antisense compounds and compositions, and a method for assaying the effectiveness of antisense delivery and uptake to a target vessel region.
... |
| Methods of producing dna and protein libraries | 20060269913 | 20061130 |
| The present invention provides a method of producing a DNA library comprising a plurality of DNA sequences of interest, where each DNA sequence of interest has at least two predetermined positions, with at each predetermined position a codon (MAX) selected from a defined group for that position, the codons within a group coding for different amino acids. The method comprising the steps of:—(i) contacting so as to effect hybridisation (a) template DNA (A) comprising said at least two predetermined positions, said template DNA being fully randomised at said at least two predetermined positions (NNN), (b) for each predetermined position, a selection oligonucleotide pool, each selection oligonucleotide (B) within each pool comprising a codon (MAX) selected from the defined group for that predetermined position, and (c) at... |
| Method for obtaining structural information about an encoded molecule | 20060269920 | 20061130 |
| Disclosed is a method for obtaining structural information about an encoded molecule, wherein the encoded molecule has been produced by a process comprising reacting a plurality of chemical entities, said chemical entities being coded for by codons on a nucleic acid template. The method comprises the steps of providing an array comprising a plurality of single stranded nucleic acid probes immobilized in discrete areas of a solid support, wherein the nucleic acid probes are capable of hybridising to a codon of the template, adding the nucleic acid template or a sequence complementary thereto, to the array under conditions which allow for hybridisation, and observing the discrete areas of the support in which an hybridisation event has occurred.
... |
| Codon-optimized genes for the production of polyunsaturated fatty acids in oleaginous yeasts | 20060270010 | 20061130 |
| The present invention relates to fatty acid desaturases and elongases able to catalyze the conversion of linoleic acid (LA) to γ-linolenic acid (GLA); α-linoleic acid (ALA) to stearidonic acid (STA); GLA to dihomo-γ-linoleic acid (DGLA); STA to eicosatetraenoic acid (ETA); DGLA to ETA; eicosapentaenoic acid (EPA) to docosapentaenoic acid (DPA); and arachidonic acid (ARA) to EPA. Nucleic acid sequences encoding codon-optimized desaturases and elongases, nucleic acid sequences which hybridize thereto, DNA constructs comprising the codon-optimized desaturase or elongases, and recombinant host microorganisms expressing increased levels of desaturase or elongase are described.
... |
| Controlled release formulations of opioid and nonopioid analgesics | 20060251721 | 20061109 |
| Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic. In a preferred embodiment, the nonopioid analgesic is acetaminophen and the opioid analgesic is hydrocodone and pharmaceutically acceptable salts thereof, and in preferred embodiments, the pharmaceutically acceptable salt is bitartrate. The dosage forms produce plasma profiles in a patient characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and an AUC for hydrocodone of between about 9.1... |
| Method of assaying interaction between proteins | 20060252028 | 20061109 |
| A novel method for determining interaction between VH fragment and VL fragment of the variable region of an antibody is provided by the present invention. The method according to this invention can be widely used for detection of protein interactions. If a phagemid vector containing an amber codon is used for transformation of an amber suppressor strain of E. coli according to the method of the invention to produce phages, both of the VH fragment and the VL fragment will be displayed on the phage particles. In contrast, if the same vector is used to transformation of an amber non-suppressing strain of E. coli to produce phages, for the presence of the amber codon, only the VH fragment will be displayed on the phage particles, while... |
| Ligational encoding of small molecules | 20060246450 | 20061102 |
| The invention relates to a method for synthesising a bifunctional complex comprising an encoded molecule and an identifier polynucleotide identifying the chemical entities having participated in the synthesis of the encoded molecule, said method comprising the steps of i) providing a) at least one template comprising one or more codons capable of hybridising to an anti-codon, wherein said template is optionally associated with one or more chemical entities, and b) a plurality of building blocks each comprising an anti-codon associated with one or more chemical entities, and ii) hybridising the anti-codon of one or more of the provided building blocks to the template, iii) covalently linking said anti-codons and/or linking the at least one template with the anti-codon of at least one building block, thereby generating... |
| Vaccine against infections caused by oncoviruses such as the feline leucosis virus of cats | 20060240034 | 20061026 |
| The invention concerns a vaccine that can induce protection against disease especially in consequence of a lentivirus infection, especially an infection with the Feline Leukosis virus. Such vaccine comprises codon-optimized DNA sequences encoding structural proteins and the most important membrane protein of FeLV.
... |
| Optimized expression of hpv 45 l1 in yeast | 20060240040 | 20061026 |
| Synthetic DNA molecules encoding the HPV45 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV45 L1 protein, wherein said polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV45 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV45 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity.
... |
| Process for producing antigenic substance | 20060233789 | 20061019 |
| An object of the present invention is to provide a means for producing an antigenic component with the retained native antigenicity using a cell-free protein synthesis. In particular, it is an object to provide a means for producing an antigenic component without depending on codon usage, like expressing an antigenic component from a gene containing a large amount of AT. The present inventors have made a strenuous study to solve the matters described above and successfully completed the present invention by preparing an antigenic component with the retained antigenicity, in particular a malaria antigen useful for manufacturing a malaria vaccine, through a system with the use of a wheat embryo among cell-free protein synthesis means.
... |
| Microarrays displaying encoded molecules | 20060234231 | 20061019 |
| Disclosed is a microarray comprising a plurality of single stranded nucleic acid probes immobilized in discrete areas of a solid support, said probes being hybridised to a library of complexes, wherein each complex comprises an encoded molecule and a template which codes for said molecule, said template comprising a number of codons which codes for chemical entities which upon reaction form a reaction product which at least partly form part of the encoded molecule.
... |
| Methods and compositions for designing nucleic acid molecules for polypeptide expression in plants using plant virus codon-bias | 20060236424 | 20061019 |
| The present invention relates to methods of designing nucleic acid molecules for improved expression of the encoded polypeptides in plants. In such methods, codon usage frequencies are biased towards codon usage frequencies of a plant virus, group of plant viruses, or a subset of nucleic acid molecules therefrom. In preferred embodiments, the encoded polypeptide affects the phenotype of the plant. The invention also pertains to nucleic acid molecules encoding insecticidal polypeptides wherein the nucleic acid molecules have been designed to have plant virus codon-biased. The invention also pertains to transgenic plants and progeny thereof with increased expression of insecticidal polypeptides for improved resistance to insects and other pests that are detrimental to plants of agricultural value.
... |
| Snps in 5' regulatory region of mdr1 gene | 20060216738 | 20060928 |
| The present invention relates to a method for determining haplotypes or diplotypes of a MDR1 gene targeting the 5′ upstream regulatory region of MDR1 gene encoding P-gp, an ABC transporter which is may be expressed in the apical membrane side and may transport a wide range of substrates. By detecting a polymorphism at −934 and/or −692, in addition to a position selected from −2903, −2410, −2352, −1910, −1717, and −1325 in a nucleotide sequence of the 5′ upstream regulatory region of MDR1 gene, haplotypes or diplotypes of the 5′upstream regulatory region of MDR1 gene may be determinable. The above positions to detect polymorphism are indicated in relation to a first base of ATG start codon which is set to +1. ATG start codon is located in... |
| Influenza nucleic acids, polypeptides, and uses thereof | 20060217338 | 20060928 |
| Codon-optimized nucleic acids encoding influenza polypeptides and uses of the nucleic acids and polypeptides for inducing immune responses are provided herein.
... |
| Recombination bcg vaccine | 20060210586 | 20060921 |
| A recombinant BCG vaccine being transformed with an expression vector that has a polynucleotide encoding a foreign antigenic protein, wherein the polynucleotide is a modified one in which a third position of each codon is substituted with G or C without a change of an amino acid. This recombinant BCG vaccine has an excellent expression rate of antigenic protein and, as a result, capable of inducing a sufficient immune response against target infectious disease, cancer, or the like at the same dose as that of the typical BCG vaccine.
... |
| Method for cultivating transgenic plants with high virus resistance and the use thereof | 20060212967 | 20060921 |
| The invention discloses a method for breeding transgenic plants with the high antiviral property and the application of the method. The inventive method comprises the following steps of: a. checking the frequency of codon usage in a host and determining the rare codons in the host, modifying the codons in a target gene so that some codons in the target gene are mutated into the rare synonymous codons in the host plant; b. constructing a vector containing the target gene with the codon modifications, to be used for transforming plants; c. transforming the plants with the above recombinant vector to obtain the regenerative transgenic plants; d. detecting the transformed plants, screening the transgenic plants in which gene silencing occurs in the target gene, and thereby obtaining... |
| Antioxidant supplement composition for smokers and ex-smokers and method of producing thereof | 20060204595 | 20060914 |
| An antioxidant supplement composition includes a mixture including 20-27% Glycyrrhiza uralensis, 2-6% Crataegus pinnatifida, 1-3% Ligusticum tenuissimum, 2-4% Acathopanax sessiliflorus, 2-5% Polygonum multiflorum, 3-6% Eugenia aromaticum, 8-10% Citrus reticulatae, 3-6% Raphani seed, 5-10% Platycodon grandiflorum, 21-26% Aloe arborescens, 18-20% Arctium lappa, 30-200 mg vitamin-C, and 1,500-20,000 IU β-carotene.
... |
| Biologic variability of asthma associated factors useful in treating and diagnosing atopic allergies including asthma and related disorders | 20060205035 | 20060914 |
| This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and... |
| Stabilized hydrocodone pharmaceutical compositions with ethylenediaminetetraacetic acid | 20060205752 | 20060914 |
| Hydrocodone pharmaceutical formulations are stabilized with a stabilizing effective amount of ethylenediaminetetraacetic compound.
... |
| Method for treating or preventing symptoms associated with menopause | 20060193929 | 20060831 |
| The present invention relates to a composition for accelerating secretion of estrogen and regenerating tissue cells of female sexual organs, and a method for treating or preventing a disease, disorder or symptom associated with menopause. The present invention uses a composition comprising as an active ingredient an extract from Cynanchum wilfordii, an extract from Phlomis umbrosa or its combination. The composition may further comprise as an active ingredient an extract from an extract from Platycodon grandiflorum and/or an extract from Angelica gigas.
... |
| Pharmaceutical combinations of hydrocodone and naltrexone | 20060194826 | 20060831 |
| Disclosed is a pharmaceutical composition comprising from about 5 to about 20 mg of hydrocodone or a pharmaceutically acceptable salt thereof and from 0.055 to about 0.56 mg naltrexone or pharmaceutically acceptable salt thereof.
... |
| Selection of host cells expressing protein at high levels | 20060195935 | 20060831 |
| The invention provides a DNA molecule comprising an open reading frame sequence that encodes a selectable marker polypeptide, wherein said DNA molecule in the coding strand comprises a translation start sequence for the selectable marker polypeptide having a GTG startcodon or a TTG startcodon, and wherein the open reading frame sequence that encodes the selectable marker protein has been mutated to replace at least half of its CpG dinucleotides as compared to the native open reading frame sequence that encodes the selectable marker protein. The invention further provides such DNA molecules wherein the open reading frame sequence that encodes a selectable marker polypeptide is part of a multicistronic transcription unit that further comprises an open reading frame sequence encoding a polypeptide of interest. The invention also... |
| Ketoreductase polypeptides and related polynucleotides | 20060195947 | 20060831 |
| The present invention is directed to variant polypeptides having enhanced ketoreductase activity and/or thermostability for use in the stereospecific reduction of ketones. In addition, the present invention is directed to polynucleotides that encode the ketoreductase polypeptides, including codon optimized versions of the polynucleotides which provide for enhanced expression in host cells. In another aspect, the present invention is directed to nucleotide constructs, vectors and host cells that are transformed with polynucleotides of the present invention.
... |
| Optimized high yield synthetic plasmids | 20060188988 | 20060824 |
| One aspect of the current invention is an optimized synthetic mammalian expression plasmid with a mutated origin of replication (e.g. “mut” family of plasmids). This new plasmid comprises a therapeutic element, and a replication element. The therapeutic element of the new plasmid comprises a eukaryotic promoter; a 5′ untranslated region (“UTR”); a codon-optimized-eukaryotic therapeutic gene sequence; and a poly adenylation signal. The therapeutic elements of this plasmid are operatively linked and located in a first operatively-linked arrangement. Additionally, the optimized synthetic mammalian expression plasmid comprises replication elements, wherein the replication elements are operatively linked and located in a second operatively-linked arrangement. The replication elements comprise a selectable marker gene promoter, a ribosomal binding site, a selectable marker gene sequence, and an improved origin of replication. The... |
| Hepatitis c virus codon optimized non-structural ns3/4a fusion gene | 20060183705 | 20060817 |
| Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.
... |
| Synthetic dna encoding an orange seapen-derived green fluorescent protein with codon preference of mammalian expression systems and biosensors | 20060183894 | 20060817 |
| Synthetic versions of a full length and termini truncated humanized green fluorescent protein based on Ptilosarcus gurneyi are disclosed which have been modified to the favored or most favored codons for mammalian expression systems. The disclosed encoded protein has 239 amino acid residues compared with the wild type Ptilosarcus gurneyi which has 238 amino acids. In the present invention, a valine residue has been added at the second position from the amino terminus and codon preference bias has been changed in a majority of the wild type codons of Ptilosarcus gurneyi fluorescent protein. The humanized Ptilosarcus gurneyi green fluorescent protein is useful as a fluorescent tag for monitoring the activities of its fusion partners using imaging based approaches.
... |
